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OBJECTIVES: To investigate the association between diastolic function and the different beneficial effects of
cardiac resynchronization therapy in patients with heart failure due to different causes.
METHODS: The 104 enrolled patients were divided into an ischemic cardiomyopathy group (n=27) and a non-
ischemic cardiomyopathy group (n=77) according to the cause of heart failure. Before implantation, left
ventricular diastolic function was evaluated in all patients using echocardiography. After six months of follow-
up, the beneficial effects of cardiac resynchronization therapy were evaluated using a combination of clinical
symptoms and echocardiography parameters.
RESULTS: The ischemic cardiomyopathy group included significantly more patients with restrictive filling than
the non-ischemic cardiomyopathy group. The response rate after the implantation procedure was significantly
higher in the non-ischemic cardiomyopathy group than in the ischemic cardiomyopathy group. Degrees of
improvement in echocardiography parameters were significantly greater in the non-ischemic cardiomyopathy
group than in the ischemic cardiomyopathy group. Multivariate regression analysis showed that a restrictive
filling pattern was an independent factor that influenced responses to cardiac resynchronization therapy.
CONCLUSIONS: This study again confirmed that the etiology of heart failure affects the beneficial effects of
cardiac resynchronization therapy and a lower degree of improvement in ventricular systolic function and
remodelling was observed in ischemic cardiomyopathy patients than in non-ischemic cardiomyopathy patients.
In addition, systolic heart failure patients with severe diastolic dysfunction had poor responses to cardiac
resynchronization therapy. Ischemic cardiomyopathy patients exhibited more severe diastolic dysfunction than
non-ischemic cardiomyopathy patients, which may be a reason for the reduced beneficial effect of cardiac
resynchronization therapy.
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’ INTRODUCTION
Cardiac resynchronization therapy (CRT) can improve
symptoms, increase quality of life, reduce the risk of hospital
readmission, and decrease the mortality of chronic heart
failure patients (1). However, approximately 30% of patients
present non-response to CRT based on current standard
guidelines (2). Substantial evidence-based medical data
indicate that the beneficial effect of CRT depends on the
etiology of heart failure. The beneficial effects of CRT are
smaller in patients with ischemic cardiomyopathy (ICM)
than in patients with non-ischemic cardiomyopathy (NICM);
therefore, ICM is a predictive factor for CRT non-response
(3,4). Given this difference in the beneficial effects of CRT
for different patients, prior studies have examined quantity
of viable myocardium, myocardial scar burden, degree of
scar transmurality, scar location, and left ventricular (LV)
pacing to assess the potential relevance of these factors (5-7).
However, the specific mechanism of these different effects
remains unclear. Diastolic function is an important compo-
nent of overall cardiac function (8). The process and degree
of diastolic dysfunction differ in different etiologies. Based
on previous findings, we hypothesized that ICM patients
who meet CRT indications exhibit more serious diastolic
dysfunction than NICM patients, which may be a reason for
the differing beneficial effects of CRT.DOI: 10.6061/clinics/2017(07)08
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Consecutive patients who were scheduled to receive CRT
pacemaker/defibrillator (CRT-P/D) treatment for chronic
heart failure at Provincial Hospital Affiliated with Anhui
Medical University from April 2013 to January 2015 were
selected. Patients who met the following criteria were
enrolled in the study (9): (1) grade III-IV on the New York
Heart Association (NYHA) functional classification after
treatment with standard drugs for heart failure; (2) sinus
rhythm, left bundle branch block (LBBB), and QRS duration
X120 ms; and (3) left ventricular ejection fraction (LVEF)
p0.35. The exclusion criteria consisted of (1) atrial fibrilla-
tion; (2) acute myocardial infarction within three months
before implantation; and (3) primary organic valvular heart
disease. A total of 106 patients were enrolled. Because two
patients suffered LV lead implantation failure, 104 patients
were included in the statistical analysis. The NICM group
consisted of 77 patients, and the ICM group comprised
27 patients. ICM was defined as X70% stenosis of at least
one major coronary artery and its large branch on coronary
angiography or a history of myocardial infarction.
Clinical evaluation
The NYHA functional classification of patients was deter-
mined before implantation, and the disease course of heart
failure, medications, and serum creatinine values were
recorded. All patients underwent 12-lead electrocardiogra-
phy (ECG) to determine heart rhythm, QRS duration, and
morphology as well as echocardiography to evaluate cardiac
structure and systolic and diastolic function. Six months after
implantation, the NYHA functional classification was re-
evaluated, and ECG and echocardiography were performed
to assess the changes.
Echocardiography
Each patient underwent conventional echocardiography
before implantation and at six months after implantation.
A Philips iE33 ultrasound system with an S5-1 probe was
used (1.0-5.0 MHz).
Left atrial as well as LV end-systolic and end-diastolic
diameters (LAD, LVESD and LVEDD, respectively) were
obtained in M mode. LV volumes and the ejection fraction
(LVESV, LVEDV and LVEF) were assessed using the biplane
Simpson’s rule. The LV outflow tract-velocity time integral
(LVOT-VTI) was measured within 0.5-1 cm below the aortic
valve, and the systolic pulmonary artery pressure (SPAP)
was estimated based on the tricuspid regurgitation velocity.
LV dyssynchrony was assessed using the standard deviation
of the time to peak systolic velocity in 12 LV segments (Ts-SD)
derived from tissue Doppler images (10).
The degree of mitral regurgitation (MR) was evalua-
ted according to the ratio between the maximal mitral
regurgitant jet area and the left atrial area as follows: mild
(Grade 1) o20%, moderate (Grade 2) 20-40%, and severe
(Grade 3) 440%.
Diastolic function was assessed by transmitral Doppler
and tissue Doppler. Pulse Doppler was used to acquire the
diastolic mitral valve flow spectrum and record peak early
diastolic velocity (E), peak late diastolic velocity (A), and
diastolic early filling deceleration time (DT) and to calculate
the E/A ratio. Tissue Doppler was used to acquire mitral
annular velocity curves corresponding to the lateral wall
and interventricular septum, to record mitral annular early
diastolic peak velocity (Em lateral and Em septal), and to
calculate the mean Em value and E/Em ratio. According
to the mitral valve flow spectrum and the tissue Doppler
spectrum of the mitral annulus, patients were divided into
restrictive filling pattern (RFP) (E/AX2, DTo160 ms, and
E/EmX13) and non-RFP (E/Ao2, DTX160 ms, and E/
Emo13) groups (11).
Placement and optimization of CRT
CRT was placed using the transvenous approach. Sub-
clavian vein puncture was performed. After coronary sinus
intubation, retrograde angiography was performed to fully
display all branches of the coronary veins. The LV electrode
lead was placed in the lateral or posterolateral cardiac vein
to ensure pacing capture, with high voltage (10 V) used to
demonstrate a lack of phrenic nerve stimulation. The right
ventricular electrode lead was placed in the right ventri-
cular apex or septum. The right atrial electrode lead was
conventionally placed in the right atrial appendage. After the
pacing tests were completed, the electrode leads were
connected to a pulse generator and embedded in a sub-
cutaneous or a deep to pectoralis major pouch in the chest
wall. The incision was sutured in layers.
Within one week of implantation, atrioventricular (AV)
delay and interventricular (VV) delay optimization were per-
formed under echocardiographic guidance. AV delay opti-
mization was conducted using the iterative method. In
particular, the optimal AV delay was determined based on
the maximum left ventricular filling times at 6 selected AV
delays: 180, 160, 140, 120, 100, and 80 ms. VV delay optimi-
zation was performed after AV delay optimization; the
optimal VV delay was determined using the maximum left
ventricular outflow tract velocity time integral at peak velo-
city (LVOT-VTImax) (12).
Six months after implantation, a X15% reduction in
LVESV compared with the preoperative value was defined
as a CRT response.
Statistical analysis
The statistical analysis was performed using SPSS 19.0
software. Continuous variables are presented as the mean±
standard deviation. Categorical variables are presented as
frequencies and percentages. Comparisons of data within
groups were performed with paired Student’s t-tests (con-
tinuous variables) and Wilcoxon signed-rank tests (NYHA
classification, MR grade). Comparisons of data between
groups were performed with unpaired Student’s t-tests
(continuous variables) and Mann-Whitney U tests (NYHA
classification, MR grade). Comparisons of gender and CRT
response rates between groups were performed with x2 tests.
Influencing factors on CRT responses were analyzed using
univariate and multivariate logistic regression models. A value
of po0.05 indicated a statistically significant difference.
’ RESULTS
1. Baseline information (Table 1). In this study, 104 patients
were enrolled, including 77 patients in the NICM group
and 27 patients in the ICM group. Before implantation, age,
gender, NYHA functional classification, PR interval, QRS
duration, serum creatinine level, echocardiography parameters
(LAD, LVEDV, LVESV, LVEF, SPAP, MR, LVOT-VTI, and
Ts-SD), and drug treatment conditions were not significantly
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different between these two groups. Compared with the NICM
group, the ICM group exhibited higher values of E/A and E/
Em and shorter DT values (po0.05 for all comparisons). The
RFP was significantly higher in patients in the ICM group than
in patients in the NICM group (51.9% vs. 24.7%, x2=6.816,
p=0.009). One week after implantation, the AV delay optimiza-
tion was not significantly different between the ICM group
(119.3±19.6 ms) and the NICM group (123.1±17.2 ms).
2. CRT response rate. Six months after the implantation
procedure, 66 out of the 104 patients (63.5%) exhibited responses
to CRT. The CRT response rate was significantly higher in the
NICM group than in the ICM group (70.1% vs. 44.4%,
x2=5.688, p=0.017).
3. Clinical beneficial effects of CRT. NYHA functional
classification, LAD, LVEDV, LVESV, LVEF, FS, and LVOT-VTI
were improved six months after the implantation procedure
relative to before implantation (po0.001 for all comparisons).
The degree of MR was lower than before implantation
(po0.05). The SPAP did not change significantly. A compar-
ison of parameters before and after CRT is presented in Table 2.
In the NICM group, the postoperative NYHA functional
classification, LAD, LVEDV, LVESV, LVEF, FS, and LVOT-VTI
were all significantly improved compared with the values
recorded before implantation (all po0.001); the degrees of
SPAP and MR were both lower than those recorded before
implantation (both po0.05). In the ICM group, the post-
operative NYHA functional classification, LVESV, LVEF, FS,
and LVOT-VTI were all significantly improved (all po0.05),
whereas the LAD, LVEDV, SPAP, and MR did not exhibit
significant changes.
Six months after implantation, the differences in echocar-
diography parameters (LVESV, LVEF, FS, SPAP, and LVOT-VTI)
between the two groups were significant (all po0.05). A com-
parison of parameters between the NICM and ICM groups is
shown in Table 3.
4. Factors that influence the CRT response (Table 4). The
univariate logistic regression analysis results suggested that
Table 2 - Clinical and echocardiographic characteristics of the
overall population at baseline and follow-up.
Parameter Baseline Follow-up p-value
NYHA class, I/II/III/IV 0/0/81/23 15/58/23/8 o0.001
LAD, mm 47.2±5.7 45.9±6.5 o0.001
LVEDV, ml 300.7±73.3 279.8±84.9 o0.001
LVESV, ml 217.6±61.4 183.0±72.9 o0.001
LVEF, % 28.2±4.9 36.0±8.9 o0.001
FS, % 13.4±2.8 17.6±4.7 o0.001
SPAP, mmHg 39.1±11.9 37.8±12.8 NS
MR grade, 1/2/3 22/68/14 42/43/19 0.043
LVOT-VTI, cm 9.9±1.7 12.9±3.8 o0.001
Table 1 - Basic Patient Data.
Parameter Total n=104 NICM n=77 ICM n=27 p-value (NICM vs. ICM)
Age, y 59.8±10.6 59.3±11.2 61.3±8.8 0.392
Male, n(%) 78 (75.0) 57 (74.0) 21 (77.8) 0.698
Disease course, y 5.2±2.9 5.3±3.0 5.0±2.7 0.600
NYHA class, n(%) III/IV 81 (77.9)/23 (22.1) 60 (77.9)/17 (22.1) 21 (77.8)/6 (22.2) 0.988
Heart rate (beats/min) 74.1±12.2 73.1±12.3 77.0±11.9 0.158
PR interval, ms 197.8±37.3 199.4±38.2 193.3±35.1 0.474
AV delay, ms 122.1±17.8 123.1±17.2 119.3±19.6 0.336
QRS duration, ms 154.3±24.8 155.6±24.7 150.7±25.0 0.384
SCr, mmol/l 88.8±29.5 88.3±28.5 90.1±32.7 0.794
LAD, mm 47.2±5.7 46.9±6.0 48.1±4.4 0.279
LVEDD, mm 74.8±8.0 74.7±7.6 75.2±9.1 0.771
LVESD, mm 64.8±7.8 64.4±7.4 65.7±9.0 0.454
LVEDV, ml 300.7±73.3 298.9±70.2 305.8±82.8 0.676
LVESV, ml 217.6±61.4 214.7±58.3 225.8±69.9 0.421
LVEF, % 28.2±4.9 28.4±4.7 27.4±5.4 0.332
FS, % 13.4±2.8 13.7±2.5 12.8±3.4 0.241
MR, n(%) 0.256
grade 1 22 (21.2) 17 (22.1) 5 (18.5)
grade 2 68 (65.4) 52 (67.5) 16 (59.3)
grade 3 14 (13.5) 8 (10.4) 6 (22.2)
SPAP, mmHg 39.1±11.9 38.4±12.0 41.2±11.4 0.290
E, cm/s 75.9±25.6 71.7±25.8 87.8±21.3 0.005
A, cm/s 64.6±17.1 67.1±17.0 57.5±15.8 0.012
E/A 1.3±0.7 1.2±0.7 1.7±0.7 0.003
DT, ms 187.3±43.8 193.9±42.1 168.3±43.9 0.008
Em septal, cm/s 5.2±1.3 5.4±1.4 4.7±1.0 0.010
Em lateral, cm/s 7.8±1.7 7.9±1.6 7.5±2.0 0.253
E/Em 12.3±5.6 11.2±5.1 15.4±6.1 0.001
LVOT-VTI, cm 9.9±1.7 10.0±1.7 9.6±1.5 0.242
Ts-SD, ms 70.3±31.5 72.6±30.6 63.8±33.7 0.215
RFP, n(%) 33 (31.7) 19 (24.7) 14 (51.9) 0.009
Diuretics, n(%) 104 (100) 77 (100) 27 (100) 1.000
ACE-I or ARB, n(%) 86 (82.7) 66 (85.7) 20 (74.1) 0.280
b-Blocker, n(%) 73 (70.2) 54 (70.1) 19 (70.4) 0.981
Amiodarone, n(%) 51 (49.0) 34 (44.2) 17 (63.0) 0.093
Spironolactone, n(%) 100 (96.2) 75 (97.4) 25 (92.6) 0.591
SCr, serum creatinine; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVEF, left ventricular ejection fraction;
MR, mitral regurgitation; SPAP, systolic pulmonary arterial pressure; LVOT-VTI, left ventricular outflow tract-velocity time integral; ACE-I, angiotensin-
converting enzyme inhibitors; ARB, angiotensin receptor blockers.
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male gender, an etiology of ischemia, a disease course of
heart failure, serum creatinine level, QRS duration, LAD,
SPAP, severe MR, and RFP influenced the CRT response.
When these factors were included in the multivariate logistic
regression analysis, the results showed that QRS duration,
LAD, and RFP were independent factors that influenced the
CRT response.
’ DISCUSSION
This study showed that (1) the improvement of left
ventricular systolic function and remodeling was redu-
ced in ischemic cardiomyopathy patients compared with
non-ischemic cardiomyopathy patients; (2) compared with
non-ischemic cardiomyopathy patients, ischemic cardiomyo-
pathy patients exhibited more severe diastolic dysfunction;
and (3) severe diastolic dysfunction (restrictive filling) was
an independent factor influencing the CRT response.
Many randomized controlled trials and observational
studies (3,4,13-15) have shown that CRT results in less impro-
vement in LV systolic function and remodeling in ICM
patients than in NICM patients. This study showed that the
ICM group had lower CRT response rates six months after
implantation; improvements in LVEF and LVOT-VTI, which
reflect LV function, and improvements in LVESV, which
reflect remodeling, were smaller in the ICM group than in
Table 4 - Univariate and multivariate logistic regression analyses: estimates of correlations between baseline clinical and
echocardiographic characteristics and response to CRT.
Parameter Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Age, y 0.986 (0.949-1.025) 0.487
Male sex 0.261 (0.082-0.831) 0.023
Ischemic etiology 0.341 (0.138-0.840) 0.019
Disease course, y 0.815 (0.701-0.948) 0.008
NYHA class IV 0.487 (0.189-1.252) 0.135
SCr, mmol/l 0.979 (0.963-0.994) 0.007
QRS duration, ms 1.038 (1.016-1.060) 0.001 1.045 (1.013-1.077) 0.006
LAD, mm 0.821 (0.749-0.901) o0.001 0.846 (0.730-0.980) 0.026
LVEDV baseline, ml 0.997 (0.992-1.003) 0.297
LVEF baseline, % 1.019 (0.938-1.108) 0.653
SPAP baseline, mmHg 0.919 (0.879-0.961) o0.001
MR baseline grade 3 0.221 (0.052-0.944) 0.042
Ts-SD, ms 1.006 (0.993-1.020) 0.361
RFP 0.123 (0.048-0.311) o0.001 0.100 (0.025-0.397) 0.001
HR, indicates hazard ratio; CI, confidence interval.
Table 3 - Clinical and echocardiographic characteristics of patients with ICM and NICM.
Parameter NICM ICM p-value
n=77 n=27
NYHA class, I/II/III/IV
Baseline 0/0/60/17 0/0/21/6 NS
Follow-up 12/45/16/4* 3/13/7/4# NS
LAD, mm
Baseline 46.9±6.0 48.1±4.4 NS
Follow-up 45.5±6.6* 47.0±6.2 NS
LVEDV, ml
Baseline 298.9±70.2 305.8±82.8 NS
Follow-up 272.6±79.9* 300.4±96.5 NS
LVESV, ml
Baseline 214.7±58.3 225.8±69.9 NS
Follow-up 174.5±67.2* 207.2±84.0# 0.045
LVEF, %
Baseline 28.4±4.7 27.4±5.4 NS
Follow-up 37.3±8.4* 32.4±9.3# 0.013
FS, %
Baseline 13.7±2.5 12.8±3.4 NS
Follow-up 18.3±4.3* 15.6±5.2# 0.008
SPAP, mmHg
Baseline 38.4±12.0 41.2±11.4 NS
Follow-up 36.0±12.1# 42.9±13.7 0.015
MR grade, 1/2/3
Baseline 17/52/8 5/16/6 NS
Follow-up 33/34/10# 9/9/9 NS
LVOT-VTI, cm
Baseline 10.0±1.7 9.6±1.5 NS
Follow-up 13.5±3.5* 11.1±3.9# 0.003
*po0.001; #po0.05; follow-up vs. baseline.
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the NICM group. These results are not surprising. Several
groups reported similar findings as long as a decade ago
(16-18). Hummel et al. proposed that their similar findings
were associated with the amount of viable myocardium (19).
Because the ICM group had a smaller amount of viable
myocardium, the improvement in LV function due to CRT
could not be maintained. Other studies have shown that
myocardial scars are associated with CRT nonresponse
(5,6,20), which has been described in relation to the myo-
cardial scar burden, degree of transmurality, and locations
of the scars and LV lead. Chalil et al. further proposed that
a scar size X33%, transmurality X51%, and pacing over a
posterolateral scar in ICM patients were associated with
suboptimal CRT responses (7). However, the specific mecha-
nism that causes different CRTcurative effects in heart failure
patients with different etiologies remains unclear. Waggoner
et al. reported that even when ICM patients exhibited impro-
ved LV systolic function, their diastolic function was not
improved compared with NICM patients, and this result was
attributed to the presence of relatively restrictive LV filling
before CRT in ICM patients and a lack of improvement of
end-diastolic volume and diastolic synchrony after CRT (21).
The present study also showed that the ICM group presented
with elevated LV filling pressures (i.e., elevated mitral E/A
and E/Em) before CRT and that LVEDV was not improved
six months after CRT.
Although diastolic function is an important component of
overall cardiac function, it has long received much less
attention than systolic function. Abnormal diastolic function
is important for the development of heart failure symptoms
and signs. Even during systolic heart failure, increased LV
filling pressure is closely associated with exercise limitation
and is independent of the degree of systolic dysfunction (8).
Studies have increasingly indicated that severe diastolic
dysfunction (restrictive filling) suggests a worse hemody-
namic and clinical status of heart failure as well as increased
mortality and heart transplantation rates (22), which is also
true for patients undergoing drug treatment (23,24), surgical
ventricular restoration (25,26), and CRT (27,28). Using multi-
variate regression analysis, this study confirmed that severe
diastolic dysfunction was an independent factor that influenced
the CRT response.
Diastolic dysfunction is a typical presentation of ICM.
Abnormal diastolic function occurs at the early stage of
myocardial ischemia, even earlier than systolic dysfunc-
tion (29,30). During myocardial ischemia, ATP produc-
tion, ATP-dependent Ca2+ pump activity, Ca2+ uptake into
the sarcoplasmic reticulum, and Ca2+ outflow decrease, and
myosin-actin complex dissociation disorder occurs, resulting
in a delayed and incomplete active diastole (31). Long-term
recurrent attacks of ischemia and infarction, myocardial necrosis,
advanced interstitial fibrosis, scar formation, increases in
ventricular stiffness, and reduction in compliance will cause
passive diastolic dysfunction, sustained increase in ventricular
filling pressure, and eventually, development of restrictive
filling (32). This phenomenon is different from dilated cardio-
myopathy, which mainly causes ventricular enlargement and
systolic dysfunction. In this study, the ICM group exhibited
more severe diastolic dysfunction than the NICM group.
Therefore, we propose that in addition to a lack of viable
myocardium and the presence of myocardial scars, the
secondary severe diastolic dysfunction in ICM patients might
also cause suboptimal improvement in LV function and
structure after CRT.
Limitations
This study is subject to the following limitations. (1) This
was a single-center observational study with no randomized
control group. (2) The composition of the underlying etio-
logies was not balanced; fewer cases of ICM were included.
(3) Invasive measurements (such as left ventricle end dia-
stolic pressure (LVEDP)) were not performed for the evalua-
tion of diastolic function. Therefore, it is necessary to increase
the sample size and validate invasive measurements to fur-
ther clarify the reason for the different curative effects of CRT
for different disease etiologies.
In summary, this study again confirmed that the etiology
of heart failure affected the curative effects of CRT and that
a lower degree of improvement of ventricular systolic func-
tion and remodeling was observed in ICM patients than in
NICM patients. In addition, systolic heart failure patients
with severe diastolic dysfunction showed poor CRT responses.
ICM patients exhibited more severe diastolic dysfunction than
NICM patients, which may be a reason for the reduced bene-
ficial effect of CRT. The findings of our study are similar to
those published as long as a decade ago, but the intervening
period has seen little attention to this important aspect of
the CRT response. We feel that it may now be reasonable to
refocus on this aspect of CRT and that a study from an Asian
country may reignite interest.
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